- n any of a large variety of proteins normally present in the body or produced in response to an antigen which it neutralizes, thus producing an immune response
- Individually, each antibody may have little effect, but as a group or even in lab-created packages of 20 to 50 antibodies they seem to confer some protection against .
- A molecular image of an antibody attacking the HIV virus may provide keys to treating the disease.
- Benveniste's researchers had diluted a solution of antibodies to such a degree that there was no likelihood that even a single molecule of the antibody remained.
News & Articles
- Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of ...
Bristol-Myers Squibb Company and AbbVie today announced updated efficacy and safety data from a small, randomized Phase 2, open-label study in patients with previously-treated multiple myeloma that evaluated two doses of the investigational monoclonal antibody elotuzumab in combination with lenalidomide and low-dose dexamethasone.
June 15, 2013 - Business Wire via Yahoo! Finance
- Immunomedics to Present at Wells Fargo Securities 2013 Healthcare Conference
MORRIS PLAINS, N.J. -- Immunomedics, Inc. , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other ...
June 14, 2013 - GlobeNewswire via Yahoo! Finance
- Omeros Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program
SEATTLE, June 13, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its...
June 13, 2013 - PR Newswire
- Paul Stoffels in Reuters India
A universal antibody or vaccine that protects against a broad range of strains would be an important advance in helping ...... control acute epidemic and pandemic outbreaks,said Paul Stoffels, head of pharmaceuticals R&D at Johnson & Johnson.
- James A Baker III in Science Daily (press release)
We found that the nanoemulsion vaccine could inactivate and kill the virus and then subsequently induce immunity to the virus that includes cellular immunity, antibody immunity and mucosal immunity,Baker says.